For the fifth year in a row
Paris, France, May 22nd, 2024 — TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the fifth year in a row in the French Tech 120 Program by joining the class of 2024.
Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the 120 most promising French start-ups, who have the potential
to become world-class technology leaders.
TISSIUM will benefit from daily, personalized support throughout the year of the 2024 class. The aim of the program is to provide individual and collective support on strategic issues such as international development, financing, recruitment, industrial implantation, intellectual property, and regulatory issues. Start-ups will thus be able to rely on a dedicated start-up manager within the Mission French Tech, enhanced visibility, specific support on regulatory issues, and collective support in the form of experience-sharing events and expertise contributions.
“We are delighted to once again be part of the French Tech 120 program, particularly during a 2024 that will mark the continued expansion of our growing business and the achievement of important clinical and regulatory milestones in preparation for the upcoming commercialization of our first products. For the fifth consecutive year, this recognition is a validation of our ongoing commitment to innovate and grow in order to transform the field of tissue reconstruction.” said Christophe Bancel, CEO of TISSIUM.
